Madison Clarke
Vaccines are a highly effective way to prevent serious illnesses, hospitalizations, and deaths. They are generally safe, but certain contraindications and precautions must be considered to avoid adverse reactions. For example, individuals with specific allergies, medical conditions, or a history of certain diseases may need to postpone or avoid certain vaccines. In the case of COVID-19, the CDC recommends waiting around three months after infection before receiving an updated vaccine, as hybrid immunity provides enhanced protection. This paragraph will explore the topic of whether any vaccinations are contraindicated for individuals who have previously had the disease in question.
Explore related products
What You'll Learn
Allergic reactions to previous vaccines or life-threatening allergies
Allergic reactions to vaccines are different from the expected side effects that can sometimes occur. There is a range of possible allergic reactions, from mild to severe or life-threatening. Mild allergic reactions can include a rash or hives. More severe allergic reactions can include symptoms like hives, throat tightness, and dangerously low blood pressure, which can cause loss of consciousness.
Anaphylaxis is the most serious type of allergic reaction. It is a severe immune response to something that is not an infection. Anaphylaxis can be life-threatening and requires immediate medical attention. Symptoms of anaphylaxis include hives, throat tightness, and dangerously low blood pressure. It is important to note that anaphylaxis is rare, occurring in about 1 in 1 million people.
If you have had an allergic reaction to a previous dose of a vaccine, such as the influenza, anthrax, cholera, or Dengvaxia vaccine, it is recommended that you inform your healthcare provider before receiving another dose of the same vaccine or a different vaccine. Additionally, if you have any severe, life-threatening allergies, it is important to disclose this information to your healthcare provider before receiving any vaccines.
In some cases, your healthcare provider may decide to postpone vaccination until a future visit or recommend alternative vaccines that do not contain the same components as the one you had an allergic reaction to. It is important to remember that vaccines are generally safe and effective, and the risk of a severe allergic reaction is rare. However, it is always recommended to discuss any concerns or previous allergic reactions with your healthcare provider before receiving a vaccine.
Equine Vaccines: 5-Way Protection for Horses
You may want to see also
Explore related products
Pregnancy and live, attenuated virus vaccines
Live attenuated vaccines (LAV) are generally contraindicated during pregnancy. This is because there is a theoretical risk that the live attenuated virus in a vaccine could cross the placenta and infect the foetus. However, it is important to note that this recommendation is based on theoretical risk rather than evidence.
The combination measles-mumps-rubella (MMR) vaccine and the varicella vaccine are examples of live attenuated vaccines that are contraindicated during pregnancy. While wild-type rubella infection can cause serious complications such as spontaneous abortion, stillbirth, and congenital rubella syndrome (CRS), there is no evidence that the MMR vaccine increases the risk of malformations, CRS, or varicella syndrome. In fact, there have been no reported cases of congenital malformations attributable to the MMR vaccine. Similarly, while maternal immunization with the rubella vaccine has been associated with intrauterine infection in infants, it does not appear to increase the risk of adverse pregnancy outcomes.
It is important to weigh the risks and benefits of vaccination during pregnancy. Pregnancy can make women more susceptible to severe manifestations of infectious diseases, which can be prevented by vaccination. Vaccination during pregnancy can also protect the unborn or newborn child through the transfer of transplacental antibodies, which can provide protection until active immunity through childhood vaccination is established.
While LAVs are generally contraindicated during pregnancy, there may be situations where the benefits outweigh the risks. For example, LAVs could play an important role in protecting pregnant women and their infants against serious emerging diseases, such as Ebola and Lassa fever. However, more research is needed to assess the safety and effectiveness of LAVs during pregnancy.
In the context of the COVID-19 pandemic, vaccination is recommended for pregnant women to protect them from severe disease and death. COVID-19 vaccines have undergone rigorous testing to ensure their safety and efficacy, and revaccination is recommended for pregnant women to maintain protection against the virus.
Air Travel and Vaccination: What's the Connection?
You may want to see also
Explore related products
Severe Combined Immunodeficiency (SCID) and rotavirus vaccines
Vaccines are one of the best ways to protect oneself from serious diseases. However, contraindications to vaccination are conditions that increase the risk of a serious adverse reaction, and vaccinations should not be administered when a contraindication is present. For example, people with a history of dengue fever or life-threatening allergies should not get the dengue vaccine, and people with a history of anthrax disease should not get the anthrax vaccine. In addition, certain vaccines, such as the yellow fever vaccine, should not be given to people who are moderately or severely ill. Severe combined immunodeficiency (SCID) is one such contraindication for rotavirus vaccines.
SCID is a rare, life-threatening disorder caused by genetic defects that result in profound deficiencies in T- and B-lymphocyte function. It is often diagnosed after an infant has acquired a severe infection, and common symptoms include chronic diarrhea, failure to thrive, and early onset of infections. The median age at diagnosis is 4-7 months, which overlaps with the ages for which rotavirus vaccination is recommended. Since the introduction of the rotavirus vaccine in the United States in 2006, several cases of vaccine-acquired rotavirus infection in infants with SCID have been reported. These infants experienced severe gastroenteritis with vaccine viral shedding and prolonged diarrhea.
Rotavirus vaccines are the only live vaccines recommended for infants in the US. The US Food and Drug Administration (FDA) has approved labeling changes for RotaTeq and Rotarix, contraindicating their administration to individuals with a history of SCID. The CDC Advisory Committee on Immunization Practices (ACIP) recommends routine immunization of infants with either a three-dose series of RotaTeq or a two-dose series of Rotarix starting at 2 months of age. However, these vaccines are not suitable for infants with SCID, as they can lead to severe gastroenteritis and prolonged diarrhea.
The risk posed by live rotavirus vaccines to individuals with SCID has been well-documented. In 2010, a search of the Vaccine Adverse Events Reporting System (VAERS) identified nine reports of SCID and rotavirus vaccination in infants between 3 and 9 months of age. Eight of these infants had diarrhea, and most had additional infections at the time of SCID diagnosis. All eight cases of vaccine-acquired rotavirus infection were confirmed by reverse transcription-polymerase chain reaction (RT-PCR) and nucleotide sequencing. This evidence highlights the importance of identifying SCID early to prevent inadvertent live rotavirus vaccine administration and potentially life-saving stem cell transplants.
In summary, severe combined immunodeficiency (SCID) is a contraindication for rotavirus vaccines due to the risk of severe adverse reactions, including gastroenteritis and prolonged diarrhea. The US Food and Drug Administration has approved labeling changes for rotavirus vaccines to contraindicate their use in individuals with SCID. It is crucial to identify SCID early and consider alternative treatments, such as stem cell transplants, to ensure the safety and well-being of infants with this rare disorder.
Vaccine Spacing and Timing: Why It Matters
You may want to see also
Explore related products
Thymus removal or thymus disorder
The yellow fever vaccine is contraindicated for people who have had their thymus gland removed (thymectomy) or have a thymus disorder, particularly those aged 60 years and older. This is because there is an increased risk of life-threatening reactions, including fatal viscerotropic disease (YEL-AVD) and neurologic disease (YEL-AND). YEL-AVD resembles severe yellow fever infection and is characterised by multisystem organ dysfunction, with 60% of reported cases proving fatal. YEL-AND includes meningoencephalitis, Guillain-Barré syndrome, acute disseminated encephalomyelitis, and cranial nerve palsies.
In 2021, the UK's CHM recommendations introduced a standardised pre-vaccination checklist to ensure the yellow fever vaccine is required for the intended travel destination and to identify any contraindications or precautions in individuals before vaccination. Healthcare professionals should ask about a history of thymus disorder or thymus removal when screening patients before administering the yellow fever vaccine. If a patient has had their thymus removed or has a thymus disorder, alternative means of prevention should be recommended, such as avoiding mosquito bites and being provided with a vaccine waiver letter.
In rare cases, people with a history of thymus removal or thymus disorder have received the yellow fever vaccine and experienced severe adverse reactions, including death. In one case, a 67-year-old woman was vaccinated with YEL approximately two years after a thymectomy for a malignant thymoma. She died three days after hospital admission due to acute respiratory failure, cardiogenic shock, and acute renal failure. Another case involved a 44-year-old Colombian man who received the vaccine two years after a thymectomy to remove a benign thymoma. He also died shortly after vaccination.
It is important to note that the decision to vaccinate should always be made after considering the individual's specific circumstances, including their travel plans, medical history, and the potential risks and benefits of the vaccine. While the yellow fever vaccine is contraindicated for people with a history of thymus removal or thymus disorder, other vaccines may still be recommended or required, depending on the specific situation and the advice of healthcare professionals.
The Challenge of Developing a Norovirus Vaccine
You may want to see also
Explore related products
Dengue infection and Dengvaxia vaccine
Dengue is a mosquito-borne tropical disease caused by the dengue virus, leading to mild, flu-like symptoms in most people. However, a small number of patients develop severe disease, with potentially fatal bleeding and organ damage. The risk of severe disease is higher in people who have been infected a second time. There are several varieties (called serotypes) of dengue virus, and Dengvaxia protects against serotypes 1, 2, 3, and 4.
Dengvaxia is a vaccine used to help protect against dengue disease in people aged 6 to 45 years who have had a previous dengue virus infection. The vaccine is given as three doses, with the initial dose followed by two additional shots given six and twelve months later. It is safe and effective when administered as recommended. Laboratory confirmation of a previous dengue infection is required for vaccination with Dengvaxia. Testing before vaccination will confirm that an individual has had dengue before.
Among children aged between 6 and 16 years who had a previous dengue infection, there were close to 80% fewer cases of dengue disease in children vaccinated with three doses of Dengvaxia compared with those given a placebo. This means that the vaccine had an efficacy of close to 80% in children who had dengue in the past. However, among children who had not had previous dengue infection, the risk of severe dengue disease if they later became infected with the virus was higher in those vaccinated than in those given a placebo.
Dengvaxia is effective at reducing the number of cases of dengue disease in people aged between 6 and 45 years who have had the infection in the past. However, people who have not had dengue infection in the past may have a higher risk of severe dengue disease if they become infected with the virus after vaccination with Dengvaxia. Therefore, the vaccine should only be given to people who have had a previous dengue infection, as confirmed by laboratory testing.
In general, vaccinations should be deferred when a precaution is present. However, vaccination might still be indicated if the benefit outweighs the risk. For example, in the case of COVID-19, hybrid immunity (protection from both vaccination and infection) enhances protection against severe disease of future COVID-19 infections and confers longer protection.
Vaccine Coverage: Does Your Insurance Plan Measure Up?
You may want to see also
Frequently asked questions
Contraindications to vaccination are conditions that increase the risk of a serious adverse reaction. Vaccines should not be administered when a contraindication is present. For example, if you have had an allergic reaction to a previous dose of a cholera vaccine, you should not receive another dose.
The CDC recommends waiting about three months after contracting COVID-19 before getting the updated vaccine. However, WHO advises that vaccination should not be delayed in anticipation of newer versions of the vaccine. Hybrid immunity from both vaccination and infection enhances protection against severe disease.
Persons who experienced encephalopathy within 7 days of receiving a vaccine containing pertussis should not receive additional doses of a vaccine containing pertussis.
You must inform your vaccination provider if you have had laboratory confirmation of a previous dengue infection.
If you have had Guillain-Barré Syndrome within 6 weeks of receiving an influenza vaccine, you should not receive another dose.
